Market Place
Sourcing Support
Jazz`s almost-withdrawn lung cancer drug shows life
16 Oct 2024 //
PR NEWSWIRE
Jazz to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca Data
15 Mar 2023 //
PR NEWSWIRE
PharmaMar Gets Approval of Zepzelca For Metastatic Small Cell Lung Cancer
09 Mar 2023 //
KALKINEMEDIA
Jazz`s lung cancer drug keeps approval despite failed trial
27 Oct 2022 //
FIERCE PHARMA
Jazz Pharma Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial
24 Mar 2022 //
PRNEWSWIRE
PharmaMar signs a new licensing and commercialization agreement with Eczacibasi
23 Dec 2021 //
PRNEWSWIRE
PharmaMar, Jazz Announce Initiation of Confirmatory Phase 3 Trial of Zepzelca
11 Dec 2021 //
PRNEWSWIRE
PharmaMar Partners with Lotus Pharmaceutical for lurbinectedin in Taiwan
11 Nov 2021 //
FIRSTWORDPHARMA
PharmaMar announces the approval of ZepzelcaTM
30 Sep 2021 //
PRESS RELEASE
New Therapy to Treat Advanced SCLC,ZEPZELCA(lurbinectedin) Approved in Singapore
22 Sep 2021 //
PRNEWSWIRE
New Therapy to Treat Advanced SCLC Approved for Australian Patients
14 Sep 2021 //
PRNEWSWIRE
Lurbinectedin/Doxorubicin Comparable to Standard of Care for SCLC, But Safer
10 Sep 2021 //
ONCLIVE
Jazz charts new path for Zepzelca after SCLC trial flop
09 Sep 2021 //
FIERCEPHARMA
European oncology group adds Pharma Mar`s Lurbinectedin to treatment guidelines
15 Apr 2021 //
REUTERS
ALX Oncology to Present ALX148 Clinical Data at (SITC) 35th
14 Oct 2020 //
GLOBENEWSWIRE
Pharma Mar S A : PharmaMar has filed lurbinectedin for Temporary Marketing
21 Jul 2020 //
MARKETSCREENER
Jazz preps first solid tumor launch with Zepzelca
22 Jun 2020 //
FIERCE PHARMA
Jazz Pharma’s $1B bet pays off with accelerated lung cancer approval
17 Jun 2020 //
ENDPTS
US FDA grants accelerated approval to Jazz Pharma’s Zepzelca
16 Jun 2020 //
PHARMABIZ
New Small Cell Lung Cancer Drug Accepted for TGA Evaluation Under Project Orbis
02 Jun 2020 //
PRNEWSWIRE
New Small Cell Lung Cancer Drug Accepted for TGA Evaluation Under Project Orbis
02 Jun 2020 //
PRNASIA
PharmaMar signs an agreement with Immedica Pharma to market lurbinectedin
29 Apr 2020 //
MARKETSCREENER
PharmaMar & Jazz Announce FDA Acceptance & Priority Review of NDA Lurbinectedin
17 Feb 2020 //
PR NEWSWIRE
Jazz rolls the dice on a billion-dollar gamble on a new drug for SCLC
19 Dec 2019 //
ENDPTS
PharmaMar files for FDA approval of small cell lung cancer drug
18 Dec 2019 //
FIERCE BIOTECH
PharmaMar files for FDA approval of small cell lung cancer drug
17 Dec 2019 //
PRESS RELEASE
Pharma Mar Gets Orphan Drug Designation For Lurbinectedin By Swiss Agency
26 Nov 2019 //
PRESS RELEASE
PharmaMar will submit NDA for lurbinectedin under accelerated approval in SCLC
19 Aug 2019 //
PR NEWSWIRE
Positive results of lurbinectedin Phase II trial from PharmaMar
04 Jun 2019 //
PR NEWSWIRE
After ovarian cancer flop, PharmaMar’s lurbinectedin makes the cut lung cancer
26 Mar 2019 //
ENDPTS
Chugai ends licence for PharmaMar’s lurbinectedin
27 Jun 2018 //
EU BIOTECHNOLOGY
Positive Recommendation of IDMC to Zepsyre® to Continue the Phase III Trial
29 May 2018 //
PR NEWSWIRE
